Dear Editor, Arterial and venous thromboembolic events are the major cause of morbidity and mortality in essential thrombocythemia (ET). Risk stratification is indispensable for choosing the appropriate patient-selective therapy [1] . Established risk factors for cardiovascular events are age above 60 years and a history of thromboembolic events [2] . In selected patients, genetic polymorphisms (Factor V Leiden, prothrombin G20210A mutation) and acquired risk factors for thrombophilia (homocysteinemia, antiphospholipid antibodies) have been described to increase the risk for thrombosis [3] [4] [5] [6] . Currently, the JAK2-V617F mutation [7] and an elevated white blood cell count [8] are considered as additional risk factors for thrombosis. However, the pathogenesis for thrombosis in these patients is still unknown. Since levels of asymmetric dimethylarginine (ADMA) are elevated in patients with cardiovascular disease and predict cardiovascular morbidity and mortality [9] , we speculated that ADMA elevation could play a role in the pathogenesis of thrombosis in ET.
The objective of this study was to investigate ADMA levels in 91 patients with ET as compared with 57 healthy individuals, and to study the association between ADMA and other clinical parameters (complete blood cell count, JAK2-V617F mutation status, body mass index, smoking history, diabetes and hypertension, and history of arterial and venous thrombosis).
For determination of ADMA levels, venous blood samples were collected at diagnosis, and plasma was separated and stored at −70°C. Analysis was performed by high-performance liquid chromatography as described previously [10, 11] . The coefficients of variation for interand intra-assay variation for this method were <3% for all analytes. The detection limit for methylarginines was 0.04 μmol/L.
ADMA plasma concentrations were significantly higher in the patient cohort than in the control group. Mean ADMA concentration in the patient cohort was 1.01 μmol/L (SD=0.49; 95% confidence interval (CI) 0.91-1.11) compared with 0.48 μmol/L (SD=0.11; 95% CI 0.45-0.51) in the control group (p<0.001). Additionally, we found a statistically significant correlation of ADMA with the platelet count (r=0.312; p=0.004). Since age cannot be excluded as a determinant of high ADMA levels and was also associated with the frequency of thrombotic events in previous studies [12] , we performed a correlation analysis of ADMA levels and age, which showed no association. Furthermore, no correlation between ADMA and laboratory parameters other than the platelet count could be found (Table 1) . ADMA levels were also not influenced by the history of arterial or venous cardiovascular events.
These findings could be a sign that ADMA is not a player in the pathogenesis of thrombosis in ET. Otherwise, they might be caused by other factors: firstly, the limited number of patients included in this study may be insufficient to reveal a statistically significant association. Secondly, the determination of ADMA levels at a single time point-the time of diagnosis-might not be sufficient to show an increase in the risk for thrombotic events during the natural disease course of ET. Finally, other yet unknown risk factors might have a greater influence on the thrombotic tendency in ET patients than ADMA.
Elevated ADMA levels have been described in several diseases, in some of which it has been shown to be an important surrogate parameter for survival. Our study demonstrates that ET has to be added to the list of disorders with elevated ADMA levels. However, the clinical importance of elevated ADMA levels in ET needs to be established in studies with larger patient cohorts. 
